Literature DB >> 12057919

Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.

Alfredo Fusco1, Gennaro Chiappetta, Pei Hui, Ginesa Garcia-Rostan, Lauren Golden, Barbara K Kinder, Deborah A Dillon, Ada Giuliano, Anna Maria Cirafici, Massimo Santoro, Juan Rosai, Giovanni Tallini.   

Abstract

Noninvasive thyroid nodules that exhibit borderline morphological signs of papillary cancer are difficult to diagnose and we do not know if they represent papillary carcinoma precursor lesions. Forty-six such nodules were analyzed for RET activation by immunohistochemistry and, in selected cases, by reverse transcriptase-polymerase chain reaction performed on RNA extracted after laser capture microdissection (LCM) of the tumor foci with and without papillary carcinoma features and positive RET immunoreactivity. RET immunoreactivity was identified, at least focally, in 30 of 46 (65.2%) of the nodules where it closely paralleled the morphological changes. Enough RNA was obtained after LCM in seven samples. RET/PTC1 or RET/PTC3 were detected in microscopic foci with papillary carcinoma features in most of the thyroid nodules (five of seven cases). No RET/PTC1 or RET/PTC3 rearrangements were detected in areas of the same tumors that lacked the cytological alterations. Analysis of clonality in the same nodules selected for LCM demonstrated that two were monoclonal and six were polyclonal. We conclude that RET activation closely parallels the morphological changes, that it is restricted to those areas of the tumor with the cytological alterations and that it is detectable in both mono- and polyclonal tumors. Although the finding of microscopic foci indicative of papillary carcinoma in a hyperplastic or adenomatous nodule does not justify the interpretation of the entire lesion as papillary carcinoma, it is possible that such foci may precede the development of invasive papillary cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057919      PMCID: PMC1850819          DOI: 10.1016/S0002-9440(10)61164-9

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells.

Authors:  M N Nikiforova; J R Stringer; R Blough; M Medvedovic; J A Fagin; Y E Nikiforov
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation.

Authors:  A Bounacer; R Wicker; B Caillou; A F Cailleux; A Sarasin; M Schlumberger; H G Suárez
Journal:  Oncogene       Date:  1997-09       Impact factor: 9.867

3.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH.

Authors:  R Cinti; L Yin; K Ilc; N Berger; F Basolo; S Cuccato; R Giannini; G Torre; P Miccoli; P Amati; G Romeo; R Corvi
Journal:  Cytogenet Cell Genet       Date:  2000

5.  Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl-2 gene.

Authors:  F Basolo; L Fiore; A Fusco; R Giannini; A Albini; G R Merlo; G Fontanini; P G Conaldi; A Toniolo
Journal:  Int J Cancer       Date:  1999-06-11       Impact factor: 7.396

6.  Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Authors:  R M Melillo; M Santoro; S H Ong; M Billaud; A Fusco; Y R Hadari; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

7.  Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.

Authors:  Y Ishizaka; S Kobayashi; T Ushijima; S Hirohashi; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

Authors:  G Tallini; M Santoro; M Helie; F Carlomagno; G Salvatore; G Chiappetta; M L Carcangiu; A Fusco
Journal:  Clin Cancer Res       Date:  1998-02       Impact factor: 12.531

9.  Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.

Authors:  T Mizuno; S Kyoizumi; T Suzuki; K S Iwamoto; T Seyama
Journal:  Oncogene       Date:  1997-09-18       Impact factor: 9.867

10.  Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.

Authors:  M Santoro; N Sabino; Y Ishizaka; T Ushijima; F Carlomagno; A Cerrato; M Grieco; C Battaglia; M L Martelli; C Paulin
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more
  33 in total

1.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 2.  Tumors of thyroid follicular epithelium: where have we been and where are we going?.

Authors:  Arthur S Tischler; Ronald A DeLellis
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 3.  Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain.

Authors:  Virginia A LiVolsi; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

Review 4.  Molecular rearrangements and morphology in thyroid cancer.

Authors:  Todd G Kroll
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

5.  Nuclear envelope irregularity is induced by RET/PTC during interphase.

Authors:  Andrew H Fischer; Panya Taysavang; Sissy M Jhiang
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

6.  Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining.

Authors:  Sofia Asioli; Francesca Maletta; Donatella Pacchioni; Rosanna Lupo; Gianni Bussolati
Journal:  Virchows Arch       Date:  2010-05-26       Impact factor: 4.064

7.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

Review 8.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

Review 9.  Handling of thyroid follicular patterned lesions.

Authors:  Juan Rosai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 10.  Diagnostic criteria in well-differentiated thyroid carcinomas.

Authors:  Elsa Fonseca; Paula Soares; Manuel Cardoso-Oliveira; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.